

---

**510(k)**  
**Summary of Safety and Effectiveness**

---

**Submitter:** Polyganics BV  
L.J. Zielstraweg 1  
9713 GX, Groningen  
The Netherlands  
[www.polyganics.com](http://www.polyganics.com)

OCT 18 2006

**Contact Person:** Jan Nieuwenhuis  
Managing Director  
Tel : +31 50 588 6588  
Fax : +31 50 588 6599  
Mobile : +31 653 211 303  
E-mail : [jan.nieuwenhuis@polyganics.com](mailto:jan.nieuwenhuis@polyganics.com)

**Date Prepared:** August 18th, 2006

---

**General Provisions:** Trade Name: Nasopore®  
Common Name: Ear Wick  
Classification Name: Ear Wick, 21 CFR 874.5220  
Device Classification: Class I non exempt.

---

**Predicate Devices:**

- Invotec Ear Tampon (Wick) w/String; Invotec Internat.; K973578
- Nasopore® nasal dressing, Polyganics, K052099

---

**Performance Standards** For the Nasopore® performance, the FDA, under section 514 of the Food, Drug and Cosmetic Act, has not established standards.

---

**Indications for Use** Nasopore® Ear is a fragmentable ear packing and is indicated for use in patients, undergoing outer ear surgery, as a space occupying stent to separate and prevent adhesions between mucosal surfaces; to help control minimal bleeding, following ear surgery, by tamponade effect and blood absorption.

---

---

**Device Description**

Nasopore® Ear is composed of a bioresorbable poly(DL-lactide-co-ε-caprolactone) urethane that fragments within several days after insertion in the outer ear, whereafter it is drained from the cavity.

The type of Nasopore® Ear is indicated on the label. Nasopore® Ear is packed in a blister closed by a medical paper lid. Nasopore® Ear is indicated for single-use.

---

**Performance Data:**

The safety and effectiveness of the Nasopore® have been demonstrated via data collected from design verification tests and analyses. The design verification testing consisted of the following:

- In vitro degradation testing
- Shelf life testing

---

**Summary of Substantial Equivalence**

The intended use of Nasopore Ear is substantially equivalent to those featured with the competitor device Invotec Ear Tampon (Wick) w/String (ref. 510(k)973578). The safety (biocompatibility) and efficacy of Nasopore® Ear is demonstrated by its substantial equivalent Nasopore® Nasal dressing (ref. 510(k)052099; Polyganics BV).

Polyganics BV already markets Nasopore® Nasal Dressing. The subject device, Nasopore® Ear, is made from the same material as Nasopore® Nasal Dressing. The subject device is substantially equivalent to Nasopore® Nasal Dressing with respect to physical characteristics and with regard to the intended use of the device, i.e. a space occupying stent to separate and prevent adhesions between mucosal surfaces and help control minimal bleeding following surgery, by tamponade effect and blood absorption, Nasopore® Nasal dressing in the nasal/sinus cavities and Nasopore® Ear in the outer ear. The predicate device Nasopore® Nasal Dressing is made of a fragmentable poly(DL-lactide-co-ε-caprolactone) urethane and the identical manufacturing process is used to produce the foam. The subject and predicate device are made of poly(DL-lactide-co-ε-caprolactone) urethane, which has demonstrated to be satisfactory biocompatible.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Polyganics BV  
c/o Jan Nieuwenhuis  
L.J. Zielstraweg 1  
9713 GX, Groningen  
The Netherlands

OCT 18 2006

Re: K062540  
Trade/Device Name: Nasopore® Ear  
Regulation Number: 21 CFR 874.5220  
Regulation Name: ENT Synthetic Polymer Material  
Regulatory Class: Class I  
Product Code: KCN  
Dated: August 21, 2006  
Received: August 30, 2006

Dear Mr. Nieuwenhuis:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "MB Eydelman, M.D.", written in a cursive style.

Malvina B. Eydelman, M.D.

Director

Division of Ophthalmic and Ear, Nose  
and Throat Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

